Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
ppm decrease » _ decrease (Expand Search), a decrease (Expand Search), pa decreased (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
ppm decrease » _ decrease (Expand Search), a decrease (Expand Search), pa decreased (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
-
201
Area V1 responses to illusory corner-folds in Vasarely’s nested squares and the Alternating Brightness Star illusions
Published 2019“…<div><p>Vasarely’s nested squares illusion shows that the corners of concentric squares, arranged in a gradient of increasing or decreasing luminance, generate illusory “corner-folds,” which appear more salient (either brighter or darker) than the adjacent flat (non- corner) regions of each individual square. …”
-
202
Flow chart of the study procedures.
Published 2023“…</p><p>Conclusions</p><p>In a mostly HIV patient population, RPR titer can show more than four-fold spontaneous increase or decrease within 1–3 months. …”
-
203
-
204
-
205
-
206
-
207
-
208
-
209
-
210
-
211
-
212
-
213
-
214
-
215
PPM1A facilitates both nuclear distribution and transcription potency of YAP/TAZ.
Published 2021“…<b>(B–D)</b> Transcription potency of YAP (5 ng), which was suppressed by coexpression of MST1 (50 ng) (B), LATS1 (500 ng) (C), or MAP4K1 (50 ng) (D), was markedly recovered by cotransfection of wild-type PPM1A but not the enzyme-dead PPM1A (D239N). …”
-
216
-
217
-
218
-
219
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
220